 Recombinant erythropoietin Medicare payment biologic recombinant human erythropoietin recent case study great influence federal policies Medicare payment exert use cost medical technologies dialysis patients Medicare predominant payer recombinant erythropoietin anemia chronic renal disease Medicare leverage low US price product fixed rate treatment biologic agent dialysis facilities financial incentive low doses Medicare monitor patients responses August average modal doses low patients months target hematocrit Medicare financial incentives payment policies quality care beneficiaries